$222.87 Million

Janux Therapeutics, Inc.

Initial Public Offering

Bookrunner, June 2021

Janux Therapeutics, Inc. (the “Company”) is an innovative biopharmaceutical company developing a next generation of tumor activated therapeutics based on the Company’s proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to better treat patients suffering from cancer. Janux’s initial focus is on developing a novel class of T Cell engagers (TCEs), and its lead product candidates target clinically validated drug targets. The Company is developing a broad pipeline with lead TCE programs targeting prostate specific membrane antigen (PSMA), Trophoblast cell surface antigen 2 (TROP2) and epidermal growth factor receptor (EGFR).

More Like This

Oct 2021
$143.8 Million

Initial Public Offering

Bookrunner

View Details
Sep 2021
$230 Million

Initial Public Offering

Bookrunner

View Details
Sep 2021
$188.5 Million

Initial Public Offering

Co-Manager

View Details